GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PolyPid Ltd.
PolyPid is an Israeli biopharmaceutical company developing extended-release drug delivery technology. Its stock price is driven by news of clinical trials of its products to prevent post-operative infections.
Share prices of companies in the market segment - Pharma infections
PolyPid is an Israeli biopharmaceutical company that has developed a technology for localized and prolonged drug delivery to prevent postoperative infections. We've categorized it under "Pharma: Infections." The chart below shows how the market views surgical innovations.
Broad Market Index - GURU.Markets
PolyPid is an Israeli biopharmaceutical company that has developed technology for localized and prolonged drug delivery to prevent post-operative infections. As a component of the GURU.Markets index, it represents the biotech sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
PYPD - Daily change in the company's share price PolyPid Ltd.
PolyPid Ltd.'s daily price change reflects the high volatility inherent in biotech companies. The indicator demonstrates sensitivity to news about clinical trials of its platform for local drug delivery after surgery.
Daily change in the price of a set of shares in a market segment - Pharma infections
PolyPid Ltd. is a biotech company. This chart highlights the sector's high volatility. Comparing it to PYPD, a platform for local drug delivery, helps assess its unique risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
PolyPid is an Israeli pharmaceutical company that has developed a technology for the sustained release of drugs after surgery. This innovative company's shares react to research data and regulatory decisions, contributing to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PolyPid Ltd.
For PolyPid Ltd., year-over-year performance is a reflection of its local drug delivery platform. Its 12-month market capitalization is entirely dependent on clinical trial data for its implants, which provide prolonged antibiotic release after surgery. Success could offer a new way to combat post-operative infections.
Annual dynamics of market capitalization of the market segment - Pharma infections
PolyPid Ltd. is an Israeli biopharmaceutical company with a unique drug delivery technology that ensures sustained release. The chart shows how the market views its innovative platform, clinical trial results, and the commercial potential of its products.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
PolyPid is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its drug delivery platform trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PolyPid Ltd.
PolyPid is a biopharmaceutical company developing extended-release drugs. Its monthly performance is entirely dependent on the results of its clinical trials. News about its interactions with the FDA and data on its key programs are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma infections
PolyPid Ltd. is developing extended-release drug delivery technology to prevent post-operative infections. This niche pharmaceutical sector addresses an important clinical need. The chart below shows how investors assessed the prospects of innovative drug delivery platforms and their commercial potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
PolyPid is an Israeli pharmaceutical company developing controlled-release drugs to prevent post-operative infections. Its stock price is dependent on the results of clinical trials and the acceptance of its technology by surgeons.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PolyPid Ltd.
PolyPid is a biopharmaceutical company developing extended-release medications to prevent post-operative infections. Weekly stock performance is volatile and depends on clinical trial news and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Pharma infections
PolyPid is a biopharmaceutical company developing extended-release medications to prevent post-operative infections. Weekly stock performance is volatile and depends on clinical trial news and regulatory decisions.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
PolyPid, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
PYPD - Market capitalization of the company PolyPid Ltd.
PolyPid's market capitalization tells the story of an Israeli biotech company developing a technology for sustained drug release after surgery. Its timeline reflects all the dramas of clinical trials, including both setbacks and new hopes. It's a visualization of the risky journey of an innovative drug delivery platform.
PYPD - Share of the company's market capitalization PolyPid Ltd. within the market segment - Pharma infections
PolyPid is a clinical-stage biopharmaceutical company developing extended-release drugs to prevent post-operative infections. Its market capitalization reflects the potential of this platform. The chart below shows the volatility associated with trial results.
Market capitalization of the market segment - Pharma infections
PolyPid has developed a technology for the sustained release of drugs directly at the surgical site to prevent infections. The graph below shows the overall market capitalization of the infectious pharmaceuticals sector. It illustrates innovative approaches to solving age-old problems, such as postoperative complications.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents "smart" drug delivery. PolyPid is developing a technology that allows for the slow release of drugs directly at the desired site, for example, after surgery to prevent infections. This graph represents the progress of this platform in clinical trials.
Book value capitalization of the company, segment and market as a whole
PYPD - Book value capitalization of the company PolyPid Ltd.
PolyPid's foundation is its PLEX technology for localized and sustained drug delivery and its financial reserves. This is a unique platform for developing new therapeutic products. The chart below shows how the Israeli biotech company manages its capital to conduct clinical trials of its lead candidates in the field of surgical infections.
PYPD - Share of the company's book capitalization PolyPid Ltd. within the market segment - Pharma infections
PolyPid is a pharmaceutical company developing technology for localized and sustained drug delivery. Its assets include R&D centers and manufacturing facilities for its unique products. The chart shows the company's share of this niche pharmaceutical infrastructure.
Market segment balance sheet capitalization - Pharma infections
Developing drug delivery systems, as the BCap_Ges chart for biotech shows, is a knowledge-intensive endeavor. PolyPid Ltd. operates in this environment. Its capital is invested in an R&D platform rather than in building giant factories.
Book value of all companies included in the broad market index - GURU.Markets
PolyPid's assets include manufacturing capacity and capital for the development of its sustained-release drug delivery platform. The book value reflects the physical foundation for the production of unique implants that slowly release antibiotics directly at the surgical site.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PolyPid Ltd.
PolyPid is developing a technology for the sustained release of drugs after surgery. The value lies in this patented platform. The book value is low. Market capitalization is an estimate of the likelihood of its products succeeding in clinical trials. MvsBCap's price chart will be driven entirely by news about the progress of these trials.
Market to book capitalization ratio in a market segment - Pharma infections
PolyPid Ltd. is a pharmaceutical company with the PLEX platform for local drug delivery. Its value lies in this unique technology. The chart shows how the market perceives the potential of its platform for improving surgical outcomes.
Market to book capitalization ratio for the market as a whole
PolyPid has developed a technology for the sustained release of drugs directly at the surgical site, reducing the risk of infection. The company's value lies in this platform. Its market valuation reflects the technology's potential to become a new standard in surgery. The graph shows the premium for solving an important clinical problem.
Debts of the company, segment and market as a whole
PYPD - Company debts PolyPid Ltd.
PolyPid, a biopharmaceutical company developing extended-release drugs to prevent post-surgical infections, is using capital to conduct clinical trials and prepare for commercialization. This chart shows how the company is funding its long and expensive journey from scientific idea to FDA-approved product.
Market segment debts - Pharma infections
PolyPid Ltd. is developing a technology for the sustained release of drugs after surgery to prevent infections. Pharmaceutical development requires significant capital. This chart shows how PolyPid is funding its clinical trials and preparations for commercialization of its innovative drug delivery platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PolyPid Ltd.
PolyPid develops extended-release drugs to prevent post-surgical infections. This chart shows its reliance on debt to fund clinical trials. High debt in this area is a bet that the company's technology will be accepted and adopted by surgeons to improve treatment outcomes.
Market segment debt to market segment book capitalization - Pharma infections
PolyPid develops drugs with extended-release technology to prevent post-surgical infections. The chart shows the debt burden in the sector. It helps understand how the company is funding the commercialization of its unique platform and how its financial strategy compares to other companies working in the surgical care field.
Debt to book value of all companies in the market
PolyPid Ltd. is a pharmaceutical company developing localized and sustained drug delivery technology to prevent surgical site infections. This chart, which shows the overall state of the market, is important for biopharma. The availability of capital to bring innovative products to market and implement them in clinical practice depends on the health of the entire ecosystem.
P/E of the company, segment and market as a whole
P/E - PolyPid Ltd.
For PolyPid Ltd., a biopharmaceutical company developing drugs to prevent post-surgical infections, this chart shows the valuation of its unique technology. The trend reflects investors' belief that its platform can significantly reduce risks for patients and become a standard in surgery.
P/E of the market segment - Pharma infections
This chart shows the average P/E valuation for the biopharmaceutical industry, where PolyPid develops drug delivery systems. This metric serves as a benchmark for assessing the premium the market is willing to pay for the company's technology, which aims to prevent post-operative infections.
P/E of the market as a whole
PolyPid develops extended-release medications that are administered directly to the surgical site to prevent infections. This chart reflects sentiment in the pharmaceutical sector. It helps understand whether the market sees the potential for PolyPid's technology to change postoperative care standards and how it assesses the company's chances of commercial success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PolyPid Ltd.
PolyPid Ltd. is a pharmaceutical company that has developed a technology for the sustained and localized release of drugs after surgery to prevent infections. The company's growth depends on the adoption of its technology by surgeons. This chart reflects analysts' belief that the company's product will become a standard in postoperative care.
%20P%2FE%20PolyPid%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PolyPid-Ltd.&v=1772557806308 "Chart of the company's future (projected) P/E PolyPid Ltd.")
Future (projected) P/E of the market segment - Pharma infections
PolyPid has developed a technology for the sustained release of drugs directly at the surgical site to prevent infections. This chart shows how its future revenue expectations compare to the industry average. Does the market believe its technology can reduce the incidence of postoperative complications?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772557806315 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
PolyPid develops drugs with extended-release technology to prevent post-operative infections. This is an innovative medical product. This chart, showing the overall market appetite for risk, influences valuations and capital availability for biotech companies. Investor optimism is helping PolyPid finance commercialization.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772557806340 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PolyPid Ltd.
PolyPid Ltd. is a biopharmaceutical company that has developed a technology for the sustained release of drugs directly at the surgical site. This helps prevent infections. Its profitability depends on the success of its products in clinical trials and their acceptance by surgeons. This graph shows the path from an innovative idea to a commercial product.
Profit of companies in the market segment - Pharma infections
PolyPid is a biopharmaceutical company that developed PLEX technology for the sustained release of drugs directly at the surgical site. Its goal is to prevent infections. This graph shows the overall profitability of a sector where innovative drug delivery platforms can significantly improve treatment outcomes and reduce complications.
Overall market profit
PolyPid develops drugs with extended-release technology after surgery. The implementation of such innovations depends on their clinical and cost-effectiveness for hospitals. The overall economic situation, reflected in the graph, influences hospital budgets and their willingness to pay more for improved treatment outcomes.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PolyPid Ltd.
PolyPid has developed a unique technology that allows for the slow, sustained release of drugs in the body. Its first product is designed to prevent post-surgical infections. This chart shows analysts' assessment of the commercial potential of this innovative drug delivery platform.
%20profit%20of%20the%20company%20PolyPid%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PolyPid-Ltd.&v=1772557806575 "Graph of future (projected) profit of the company PolyPid Ltd.")
Future (predicted) profit of companies in the market segment - Pharma infections
PolyPid Ltd. has developed PLEX (Polymer-Lipid Encapsulation Matrix) technology, which enables sustained and controlled release of drugs directly at the site of action. Their leading product is aimed at preventing postoperative infections. This graph shows profitability projections for the pharmaceutical sector, reflecting the potential of innovative drug delivery systems.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772557806597 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
PolyPid Ltd. is a pharmaceutical company developing technology for local drug delivery to prevent postoperative infections. The adoption of its products depends on hospital budgets and their desire to reduce the cost of treating complications. This schedule, reflecting the overall economic situation, affects the financial capacity of the healthcare system.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772557806688 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PolyPid Ltd.
PolyPid Ltd. develops drugs using extended-release technology. This chart shows the market valuation of its innovative platform. The high valuation relative to sales reflects the potential of its technology to improve treatment outcomes and reduce complications.
P/S market segment - Pharma infections
PolyPid Ltd. is a pharmaceutical company that has developed a technology for the sustained release of drugs directly at the site of action. This chart shows the average revenue estimate in the biotech sector. It allows us to estimate the premium investors are placing on the potential of the PLEX platform to improve surgical outcomes and treat infections.
P/S of the market as a whole
PolyPid developed PLEX technology, which enables sustained and localized drug release directly at the surgical site, for example, to prevent infections. This chart, showing the valuation of companies with real revenues, highlights the high hopes investors have for innovative drug delivery platforms.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PolyPid Ltd.
PolyPid has developed a technology that delivers medications to the body over a prolonged period, preventing post-surgical infections. This graph reflects market expectations for this platform. The estimate is based on future sales of its products, which could reduce the incidence of post-surgical complications and healthcare costs.
%20P%2FS%20PolyPid%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PolyPid-Ltd.&v=1772557806777 "The graph of the company's future (projected) P/S PolyPid Ltd.")
Future (projected) P/S of the market segment - Pharma infections
PolyPid is a pharmaceutical company developing technology for localized and sustained drug delivery directly to the surgical site to prevent infections. This chart shows how the market views its innovative drug delivery platform compared to the pharmaceutical sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772557806798 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
PolyPid is a biopharmaceutical company that has developed a technology for the sustained release of drugs directly at the surgical site to prevent infections. This graph, reflecting the healthcare system's willingness to invest in improving treatment outcomes, is important to PolyPid. Economic growth allows hospitals to implement new technologies that reduce complications.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772557806827 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PolyPid Ltd.
PolyPid is a pharmaceutical company that developed PLEX technology for localized and sustained drug delivery. This chart shows revenue that could come from partnerships or initial sales of its first product for the prevention of post-operative infections. It reflects the commercialization of this innovative drug delivery platform.
Sales of companies in the market segment - Pharma infections
PolyPid Ltd. is a biopharmaceutical company developing products with sustained and controlled drug release technology to prevent post-operative infections. Its business is segmented by various products in development. This chart shows the cash flows associated with one of its lead candidates, reflecting its clinical progress.
Overall market sales
PolyPid Ltd. is a pharmaceutical company that has developed a technology for the sustained release of drugs directly at the surgical site. This helps prevent infections and reduce pain. The company's success depends on the implementation of its technology in surgical practice and is an example of innovation aimed at improving treatment outcomes and reducing costs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PolyPid Ltd.
PolyPid is a biopharmaceutical company that developed PLEX technology for localized and sustained drug delivery. Its future sales forecast is based on the anticipated commercial success of its first product for preventing postoperative infections. This is a bet that its technology will improve surgical outcomes.
%20sales%20of%20the%20company%20PolyPid%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PolyPid-Ltd.&v=1772557806899 "Schedule of future (projected) sales of the company PolyPid Ltd.")
Future (projected) sales of companies in the market segment - Pharma infections
PolyPid Ltd. has developed a technology for the sustained release of drugs directly at the surgical site to prevent infections. This graph shows expectations for the infectious diseases sector. It helps assess the demand analysts predict for solutions to combat post-operative complications.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772557806920 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
PolyPid develops extended-release medications to prevent post-operative infections. Demand for its technology depends on hospitals' willingness to innovate to improve treatment outcomes. This chart of overall sales forecasts reflects the economic climate, which impacts healthcare budgets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772557806938 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PolyPid Ltd.
PolyPid Ltd. is a commercialization-stage pharmaceutical company that has developed a technology for the sustained release of drugs directly at the site of surgical intervention. This graph shows its path to profitability, where revenue from initial sales begins to offset the costs of manufacturing and marketing the innovative product.
Market segment marginality - Pharma infections
PolyPid is developing a technology for the sustained release of drugs directly at the site of action, for example, after surgery. Their goal is to improve the efficacy and safety of existing drugs. The graph shows their operating costs towards commercialization of this innovative pharmaceutical platform.
Market marginality as a whole
PolyPid Ltd. is a pharmaceutical company developing a technology for the sustained release of drugs directly at the surgical site. This helps prevent infections. This graph shows average profitability, but for PYPD, success depends on the ability of its technology to improve surgical outcomes and become a new standard of care.
Employees in the company, segment and market as a whole
Number of employees in the company PolyPid Ltd.
PolyPid has developed a platform for localized, long-term drug delivery. This graph shows the team's scientists and clinicians. This team's growth is directly related to advancing their products through clinical trials, particularly in the area of preventing post-surgical infections.
Share of the company's employees PolyPid Ltd. within the market segment - Pharma infections
PolyPid Ltd. has developed a technology for the sustained release of drugs directly at the surgical site, helping prevent infections. Commercializing this platform requires a manufacturing and sales team. This reflects its extensive expertise in the advanced drug delivery systems niche.
Number of employees in the market segment - Pharma infections
PolyPid Ltd. has developed a technology for the sustained release of drugs directly at the surgical site. This graph shows employment in the infectious diseases sector of the pharmaceutical industry. The growing number of specialists in this field highlights the problem of postoperative infections and the need for innovative solutions to prevent them.
Number of employees in the market as a whole
PolyPid develops drugs to prevent surgical site infections. Demand for its products is driven by the number of surgeries and hospitals' desire to reduce complications. This graph shows the overall economics, but for PolyPid, proving the clinical and cost-effectiveness of its technology is more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PolyPid Ltd. (PYPD)
PolyPid Ltd. is a pharmaceutical company developing extended-release drugs to prevent surgical site infections. The high market capitalization per employee in this chart highlights the value of its PLEX technology platform. The market evaluates the potential of the technology, not the size of its workforce or production capacity.
%20of%20the%20company%20PolyPid%20Ltd.%20(PYPD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PolyPid-Ltd.-PYPD&v=1772557807498 "Chart of market capitalization per employee (in thousands of dollars) of the company PolyPid Ltd. (PYPD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
PolyPid Ltd. is a pharmaceutical company developing a platform for localized and sustained drug delivery. This metric reflects how the market perceives their unique PLEX technology and its potential to improve surgical outcomes. It is a measure of the value of their innovative platform per team.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772557807534 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
PolyPid Ltd. is a pharmaceutical company that has developed a technology for the sustained release of drugs directly at the surgical site to prevent infections. The chart shows the market perception of this innovative drug delivery platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772557807575 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PolyPid Ltd. (PYPD)
PolyPid Ltd. is a biopharmaceutical company that developed PLEX technology for localized, sustained drug delivery (e.g., antibiotics to surgical wounds). It is a clinical-stage R&D company. This negative graph shows the capital invested in each scientist to commercialize this platform, which aims to improve surgical outcomes.
%20Chart%20PolyPid%20Ltd.%20(PYPD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PolyPid-Ltd.-PYPD&v=1772557807603 "Company Profit Per Employee (in thousands of dollars) Chart PolyPid Ltd. (PYPD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
PolyPid Ltd. is a biopharmaceutical company that developed PLEX technology for localized, long-term drug delivery, such as after surgery. Their success depends on the commercialization of this platform. This chart shows how effectively their team is turning innovative technology into a profitable product compared to other pharmaceutical companies.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772557807613 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
PolyPid (PYPD) is a pharmaceutical company developing a platform for local drug delivery (for example, after surgery). The company is in the R&D stage. Negative profit per employee is normal. The chart shows the "cost" of the team of scientists working on this technological platform, which does not yet generate revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772557807650 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PolyPid Ltd. (PYPD)
PolyPid is a biopharmaceutical company that has developed a technology for the sustained release of drugs after surgery. This graph shows its path to commercialization. Growth in revenue per employee will reflect the successful implementation of its products to prevent post-operative infections.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PolyPid-Ltd.-PYPD&v=1772557807705 "Sales chart per company employee PolyPid Ltd. (PYPD)")
Sales per employee in the market segment - Pharma infections
PolyPid is a biopharmaceutical company that developed PLEX technology for the sustained and controlled delivery of drugs (such as antibiotics) directly to the surgical site. This chart compares PolyPid's revenue per employee to the industry average, demonstrating the commercial viability of their unique drug delivery platform.
Sales per employee for the market as a whole
PolyPid (PYPD) is an Israeli biotech company that has developed a platform (PLEX) for prolonged drug delivery directly to the site of infection (e.g., after surgery). The company is in the late clinical stage and has no commercial revenue yet. This graph will reflect $0 until FDA approval.
Short shares by company, segment and market as a whole
Shares shorted by company PolyPid Ltd. (PYPD)
PolyPid (PYPD) is an Israeli biotech company that has developed a capsule technology for the slow release of drugs (such as antibiotics) directly into a surgical wound. The idea is sound, but the company has encountered failures in trials. This chart shows the number of investors who don't believe this technology works.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PolyPid-Ltd.-PYPD&v=1772557807830 "Short Shares Chart for the Company PolyPid Ltd. (PYPD)")
Shares shorted by market segment - Pharma infections
PolyPid (PYPD) is an Israeli biopharmaceutical company that developed "PLEX" technology for sustained and controlled drug release directly at the surgical site. This chart shows the odds against the drug delivery sector, reflecting investor doubts that this technology will prove its advantage in clinical trials.
Shares shorted by the overall market
PolyPid is a biotech company developing long-term drug delivery systems to prevent post-surgical infections. This chart reflects the overall market pessimism. Investors see a company dependent on successful R&D and regulatory approval. In times of fear, any delay or setback is perceived as a failure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PolyPid Ltd. (PYPD)
PolyPid Ltd. is an Israeli biotech developing the PLEX platform for local drug delivery to prevent post-surgical infections. This chart tracks volatility associated with trial news, showing "overheating" (above 70) on positive data or "oversold" (below 30) on news of trial pauses.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PolyPid-Ltd.-PYPD&v=1772557807940 "RSI 14 indicator chart for the company's stock PolyPid Ltd. (PYPD)")
RSI 14 Market Segment - Pharma infections
PolyPid Ltd. is a biopharmaceutical company that developed PLEX technology for controlled drug release. Its products are designed to prevent infections after surgery. This chart measures the overall momentum in the infectious disease biotech sector. It helps separate PYPD's momentum from the general industry hype.
RSI 14 for the overall market
PolyPid (PYPD) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PYPD (PolyPid Ltd.)
PolyPid is a biotech company developing D-PLEX technology for the sustained release of drugs (such as antibiotics) directly at the surgical site. This chart shows the average target price. Analysts' forecasts are based on clinical data and D-PLEX's potential to prevent postoperative infections.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PYPD-PolyPid-Ltd.&v=1772557808067 "A chart showing analyst consensus forecasts for the expected stock price. PYPD (PolyPid Ltd.)")
The difference between the consensus estimate and the actual stock price PYPD (PolyPid Ltd.)
PolyPid is an Israeli biotech company with the PLEX platform. It creates implants that slowly release medication (such as an antibiotic) directly at the surgical site. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in this technology for preventing post-surgical infections.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PYPD-PolyPid-Ltd.&v=1772557808161 "A chart showing the difference between the consensus forecast and the actual stock price. PYPD (PolyPid Ltd.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
PolyPid is an Israeli biotech company that has developed a "smart" sponge (D-PLEX) that delivers antibiotics directly to surgical wounds, preventing infections. This chart shows the general expectations of pharmaceutical analysts, reflecting their confidence in the success of this localized drug delivery technology.
Analysts' consensus forecast for the overall market share price
PolyPid is an Israeli biotech company that has developed the "PLEX" platform for sustained drug delivery (such as antibiotics) directly into surgical wounds. This chart shows the overall risk appetite. For PolyPid, a clinical-stage company with an innovative platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PolyPid Ltd.
PolyPid is a drug-depositing sponge. This Israeli company developed PLEX, a biodegradable sponge that slowly releases antibiotics directly into surgical wounds to prevent infections. This graph is purely an indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma infections
PolyPid (PYPD) is an Israeli pharmaceutical company developing extended-release medications based on its PLEX platform. Their goal is to prevent surgical infections by delivering antibiotics directly to the wound. The chart shows the segment average, helping investors assess how this technology compares to the sector average.
The AKIM Index for the overall market
PolyPid is a pharmaceutical company that developed PLEX technology for localized, sustained-release drug delivery (for infection prevention). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is seeking approval for its main product, compares to overall trends.
